918 results on '"Capasso, Anna"'
Search Results
2. Population-level comparisons of gene regulatory networks modeled on high-throughput single-cell transcriptomics data
3. Paliperidone in the treatment of Schizophrenia: An overview.
4. Topiramate in the Treatment of Obesity Induced by Psychotropic Drugs in a Patient with Bipolar Disorder: A Case Report
5. Gain and loss of upper limb abilities in Duchenne muscular dystrophy patients: A 24-month study
6. Profile of cognitive abilities in spinal muscular atrophy type II and III: what is the role of motor impairment?
7. Patient reported outcome measure for upper limb in Duchenne muscular dystrophy: correlation with PUL2.0.
8. Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies
9. Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening
10. Assessing floppy infants: a new module
11. #883 P-cresyl sulphate and Indoxyl sulphate: two uremic toxins stimulating colon cancer progression in patients with chronic renal failure
12. Long term follow-up of scoliosis progression in type II SMA patients
13. Meet the Co-Editor
14. Communicative development inventory in type 1 and presymptomatic infants with spinal muscular atrophy: a cohort study
15. Can the CHOP-INTEND be used as An Outcome Measure in the First Months of Age? Implications for Clinical Trials and Real World Data
16. Current methods in translational cancer research
17. How to assess kidney function in oncology patients
18. DNA‐Barcoded Plasmonic Nanostructures for Activity‐Based Protease Sensing
19. High glucose concentration produces a short-term increase in pERK1/2 and p85 proteins, having a direct angiogenetic effect by an action similar to VEGF
20. The renal adverse effects of cancer immunotherapy
21. Early treatment of type II SMA slows rate of progression of scoliosis.
22. DNA‐Barcoded Plasmonic Nanostructures for Activity‐Based Protease Sensing.
23. Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy
24. BRAF fusions identified in melanomas have variable treatment responses and phenotypes
25. RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer
26. Possible Effects of Uremic Toxins p-Cresol, Indoxyl Sulfate, p-Cresyl Sulfate on the Development and Progression of Colon Cancer in Patients with Chronic Renal Failure
27. Impact of Thyroid Cancer Treatment on Renal Function: A Relevant Issue to Be Addressed
28. Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies
29. Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability?
30. Data from First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer
31. Supplementary Figure S1 from First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer
32. Supplementary Tables and Figures from Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms
33. Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment
34. Clinical Phenotype of Pediatric and Adult Patients With Spinal Muscular Atrophy With Four SMN2 Copies: Are They Really All Stable?
35. Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors
36. Supplementary Table S5 from Integrated Genomic Characterization of the Human Immunome in Cancer
37. Supplementary Table 1 from Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells
38. Supplementary Figure Legend from Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells
39. Supplementary Figure 2 from Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells
40. Supplementary Figures from Integrated Genomic Characterization of the Human Immunome in Cancer
41. Supplementary Figure 1 from Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells
42. Supplementary Figures 1 - 3, Tables 1 - 3 from Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition
43. Supplementary Table 2 from Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells
44. Supplementary Figure Legends from Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition
45. Supplementary Figure S1 from Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors
46. Neurobiological Correlates Shared Between Obesity, BED and Food Addiction
47. Population-level comparisons of gene regulatory networks modeled on high-throughput single-cell transcriptomics data
48. A Longitudinal Follow-Up Study of Intellectual Function in Duchenne Muscular Dystrophy over Age: Is It Really Stable?
49. Development of Several Pharmaceutical Formulations of Cannabinoids in Cancer Drug Discovery
50. Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.